NEW YORK (GenomeWeb) – MiR Scientific, formerly MiR Diagnostics, hopes to launch its first clinical cancer test within the next year, after spending the last several years conducting validation studies of its technology, which involves analysis of microRNA and other small noncoding RNA (sncRNA) molecules in urine.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.